ClinicalTrials.gg
CompletedNCT04066257Updated Aug 28, 2019

Evaluate the PK of Multiple Oral Doses of Tegoprazan, Metronidazole, Tetracycline and Bismuth in Healthy Volunteers

A Phase 1 interventional study of Tegoprazan and Metronidazole in Healthy, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-28.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jan 2019, registered Aug 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

This study aims to evaluate the pharmacokinetic interaction between tegoprazan and combination of metronidazole, tetracycline and bismuth in healthy adult volunteers.

Read the detailed description

A open-label, randomized, multiple dose, two arm, two period, crossover study

02

Conditions studied

  • Healthy

Keywords

  • Drug-Drug interaction
  • pharmacokinetic
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult aged ≥ 19 and \< 55 year-old on the day of obtaining the .
  • (BMI) ≥ 17.5 kg/m2 and \< 28.0 kg/m2 with a body weight ≥ 55 kg at screening.
  • H. pylori negative.

Exclusion criteria

Exclusion Criteria:

  • Medical History

    1. History or evidence of disease
    2. History of gastrointestinal disease (e.g., esophageal disease such as esophageal achalasia or stenosis, and Crohn's disease) or surgery that may affect the absorption of a drug.
    3. History or presence of to IMPs, components of IMPs, benzimidazoles, imidazole derivatives or tetracycline antibiotics
  • Laboratory tests(in blood)

    1. Total , (GOT), ALT (GPT) > 1.5 X (ULN) at screening
  • History of drug/alcohol abuse
  • Participated in other study and received product within 3 months prior to the first study dose.
  • taken a medication known to substantially induce or inhibit a drug metabolizing enzyme
  • Not able to use a medically acceptable method throughout the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Tegoprazan 50 mg

    Oral administration of Tegoprazan 50 mg twice daily for 7 days

    Drug: Tegoprazan

  • Active comparator
    Tegoprazan 50 mg+MTN 500 mg+TCL 500 mg+BIS 300 mg

    Oral administration of Tegoprazan 50 mg twice daily, Metronidazole 500 mg three times daily, and Tetracycline hydrochloride 500 mg \& Tripotassium bismuth dicitrate 300 mg four times daily for 7 days

    Drug: Tegoprazan · Drug: Metronidazole · Drug: Tetracycline · Drug: Bismuth

  • Active comparator
    MTN 500 mg+TCL 500 mg+BIS 300 mg

    Oral administration of Metronidazole 500 mg twice daily, Tetracycline hydrochloride 500 mg \& Tripotassium bismuth dicitrate 300 mg four times daily for 7 days

    Drug: Metronidazole · Drug: Tetracycline · Drug: Bismuth

Interventions

  • Tegoprazan 50 mg tablet

    Also known as: K-CAB

  • Metronidazole 250 mg tablet

    Also known as: Flasinyl

  • Tetracycline hydrochloride 250 mg capsule

    Also known as: Teracyclin

  • Tripotassium bismuth dicitrate 300 mg tablet

    Also known as: Denol

06

What researchers measure

Primary outcomes

  1. AUC0-12 of tegaprazan and metabolite M1

    Area under the plasma concentration versus time curve of tegoprazan

    Time frame: pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in period1 ,2.

  2. Cmax of tegaprazan and metabolite M1

    Peak Plasma Concentration of tegoprazan and metabolite M1

    Time frame: pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in period1 ,2.

  3. AUC0-6 of metronidazole, tetracycline and bismuth

    Area under the plasma concentration versus time curve of metronidazole, tetracycline and bismuth

    Time frame: pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in period1 ,2.

  4. Cmax of metronidazole, tetracycline and bismuth

    Peak Plasma Concentration of metronidazole, tetracycline and bismuth

    Time frame: pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in period1 ,2.

07

Study locations

1 site
  • Chonbuk National University Hospital
    Jeonju, Korea, Republic of
08

References and documents

Publications

  • Jeon JY, Kim SY, Moon SJ, Oh K, Lee J, Kim B, Song GS, Kim MG. Pharmacokinetic Interactions between Tegoprazan and Metronidazole/Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects. Clin Ther. 2021 Apr;43(4):722-734. doi: 10.1016/j.clinthera.2021.01.026. Epub 2021 Feb 23. PubMed 33637332 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Feb 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2019
First posted
Aug 26, 2019
StartActual
Jan 17, 2019
Primary completionActual
Feb 22, 2019
CompletionActual
Apr 25, 2019
Last update
Aug 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04066257
Responsible party
Sponsor
First posted
Aug 26, 2019
Start date
Jan 17, 2019
Primary completion
Feb 22, 2019
Completion
Apr 25, 2019
Last update
Aug 28, 2019

Study contacts

Min-Gul Kim, MD
principal investigator · Chonbuk university hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tegoprazan · Metronidazole · Tetracycline · Bismuth

Start the discussion